Indegene Reports Strong FY26 Performance with ₹401 Cr Profit; Proposes ₹2.25 Dividend

Financial Performance and Dividend Proposal

Indegene Limited's Board of Directors met on April 29, 2026, to approve the audited financial results for the fiscal year and quarter ended March 31, 2026. The company posted a consolidated Profit After Tax (PAT) of ₹4,011 million (₹401.10 crore) for FY2026, on consolidated revenues of ₹35,105 million (₹3,510.50 crore). For the fourth quarter of FY2026, consolidated PAT was ₹797 million (₹79.70 crore) on revenues of ₹10,034 million (₹1,003.40 crore). Additionally, the Board recommended a final dividend of ₹2.25 per equity share for FY2026, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Why the Results Matter

Indegene's strong financial results, especially its profit after tax, highlight its operational effectiveness and position within the life sciences commercialization sector. The proposed dividend provides a direct shareholder return, indicating confidence in future earnings. However, the company must also manage provisions for legal matters and potential tax adjustments, which represent ongoing risks to profitability.

Company Background and Legal History

Indegene, a digital-first firm focused on life sciences commercialization, has seen significant growth since its IPO in May 2024. Globally, it competes with companies like IQVIA and Syneos Health, utilizing AI and digital tools for biopharma clients. The company has previously accounted for risks, setting aside ₹203 million as of March 31, 2024, for a US class action lawsuit over alleged TCPA violations. It has also navigated transfer pricing disputes in India, where tax authorities have proposed adjustments.

What This Means for Shareholders

Shareholders are set to vote on the proposed final dividend of ₹2.25 per share at the upcoming Annual General Meeting. The company's latest financial statements officially include the provision made for the US TCPA lawsuit. Investors will be watching closely for updates on the resolution of the draft transfer pricing order and any new information regarding the US legal case.

Detailed Risk Disclosures

• US TCPA Lawsuit: Indegene has recognized a provision of ₹203 million for a class action lawsuit alleging TCPA violations in the United States.
• Transfer Pricing Dispute: A draft order concerning transfer pricing proposes adjustments totaling ₹1,114 million. The company is pursuing resolution through the Mutual Agreement Procedure (MAP). No provision has been made for this, with the potential exposure noted as a contingent liability.

Competitive Landscape

Indegene operates in the specialized field of life sciences commercialization. While Indian healthcare providers like Apollo Hospitals and Max Healthcare are in a different sector, Indegene's direct competitors in digital services are mainly global players such as IQVIA and Syneos Health. Indegene's key differentiator is its combination of deep life sciences expertise with advanced digital solutions, AI, and data analytics.

What to Watch For

• The outcome of the shareholder vote on the final dividend at the AGM.
• How the US TCPA class action lawsuit is resolved and its financial impact.
• Progress and outcome of the Mutual Agreement Procedure (MAP) for the transfer pricing dispute.
• Indegene's future financial performance, including revenue growth and how contingent liabilities affect results.